Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amylyx Pharmaceuticals, Inc.AMLX · Entity 259 | Director | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amylyx Pharmaceuticals, Inc.
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,900 |
Ending reported balance
After 2026-08-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-31 · Exercise / conversion · Acquired 25,000 · Balance 91,900 Row 2 · 2026-08-31 · Exercise / conversion · Acquired 25,000 · Balance 116,900 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.76 · Expires 2034-06-05 | Direct | 0 |
Reported balance
After 2026-08-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-31 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: This option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.05 · Expires 2035-06-04 | Direct | 0 |
Reported balance
After 2026-08-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-31 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: This option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 20:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0001193125-26-380152 · ownership.xml · derivative · entry 4 Firestone Karen · CIK 0001969821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2035-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 20:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001193125-26-380152 · ownership.xml · derivative · entry 3 Firestone Karen · CIK 0001969821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2034-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 20:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | Exercise / conversionCommon Stock | 25,000 | $5.05 | $126,250.00 |
DisclosureSEC source: 0001193125-26-380152 · ownership.xml · nonDerivative · entry 2 Firestone Karen · CIK 0001969821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 20:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | Exercise / conversionCommon Stock | 25,000 | $1.76 | $44,000.00 |
DisclosureSEC source: 0001193125-26-380152 · ownership.xml · nonDerivative · entry 1 Firestone Karen · CIK 0001969821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 24,372 | $0.00 Strike: $14.31 | $0.00 |
DisclosureSEC source: 0001193125-26-261641 · ownership.xml · derivative · entry 1 Firestone Karen · CIK 0001969821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,372 Underlying: Common Stock · 24,372 shares Expires 2036-06-03 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | PurchaseCommon Stock | 3,800 | $13.51 | $51,338.00 |
DisclosureSEC source: 0001193125-26-239216 · ownership.xml · nonDerivative · entry 1 Firestone Karen · CIK 0001969821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,900 Read SEC document |
| December 23, 2025 Filed Dec 24, 2025 01:48 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | PurchaseCommon Stock | 8,100 | $12.45 | $100,845.00 |
DisclosureSEC source: 0001193125-25-331289 · ownership.xml · nonDerivative · entry 1 Firestone Karen · CIK 0001969821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,100 Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:08 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000950170-25-083719 · ownership.xml · derivative · entry 1 Firestone Karen · CIK 0001969821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2026 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| September 05, 2024 Filed Sep 9, 2024 20:05 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | PurchaseCommon Stock | 50,000 | $2.13 | $106,590.00 |
DisclosureSEC source: 0000950170-24-104737 · ownership.xml · nonDerivative · entry 1 Firestone Karen · CIK 0001969821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.11 to $2.15. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:50 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0000950170-24-070804 · ownership.xml · derivative · entry 1 Firestone Karen · CIK 0001969821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 6, 2025 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 21:37 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | PurchaseCommon Stock | 4,000 | $14.97 | $59,880.00 |
DisclosureSEC source: 0000950170-23-071533 · ownership.xml · nonDerivative · entry 1 Firestone Karen · CIK 0001969821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 23:50 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 3,908 | $0.00 Strike: $26.25 | $0.00 |
DisclosureSEC source: 0000899243-23-015412 · doc4.xml · derivative · entry 1 Firestone Karen · CIK 0001969821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,908 Underlying: Common Stock · 3,908 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 8, 2024 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:22 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (Right to Buy) · Derivative | 27,403 | $0.00 Strike: $32.08 | $0.00 |
DisclosureSEC source: 0000899243-23-009172 · doc4.xml · derivative · entry 2 Firestone Karen · CIK 0001969821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,403 Underlying: Common Stock · 27,403 shares Expires 2033-03-16 F2 · derivative.exercise_date: One-third of the shares subject to the option shall vest on the first anniversary of the date of grant, and the remaining two-thirds will vest in equal monthly installments over two years, provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director of the Issuer. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:22 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | PurchaseCommon Stock | 1,000 | $31.99 | $31,990.00 |
DisclosureSEC source: 0000899243-23-009172 · doc4.xml · nonDerivative · entry 1 Firestone Karen · CIK 0001969821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.96 to $32.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.